New York: A 10-minute image-guided minimally invasive procedure can help restore the sense of smell in patients who have suffered with long-Covid, according to new research.
Parosmia, a condition where the sense of smell no longer works correctly, is a known symptom of Covid-19. Recent research has found that up to 60 per cent of Covid patients have been affected.
To assess a possible treatment for patients with long-term post-Covid parosmia, researchers looked at the potential benefits of CT-guided stellate ganglion block.
Part of the autonomic nervous system, which regulates involuntary processes including heart rate, blood pressure, breathing and digestion, the stellate ganglia are nerves on each side of the neck. They deliver certain signals to the head, neck, arms and a portion of the upper chest.
The research team used a stellate ganglion block, which includes injecting anaesthetic directly into the stellate ganglion on one side of the neck to stimulate the regional autonomic nervous system.
The minimally invasive procedure takes less than 10 minutes, and no sedation or intravenous analgesia is necessary.
Stellate ganglion block has been used with varying degrees of success to treat a number of conditions, including cluster headaches, phantom limb pain, Raynaud’s and Meniere’s syndromes, angina and cardiac arrhythmia.
“Parosmia has previously been reported as a rare disorder occurring after brain trauma, brain surgery, stroke, viral syndromes, and with some head and neck tumours,” Zoga said. “We were not entirely confident that the procedure would work for parosmia.”
For the study, 54 patients were referred from an ear, nose and throat specialist after at least six months of post-Covid parosmia that was resistant to pharmaceutical and topical therapies.
CT guidance was used to position a spinal needle at the base of the neck for injection into the stellate ganglion.
The researchers added a small dose of corticosteroid to the anaesthetic in the pharmacologic preparation, suspecting that the Covid virus may be causing nerve inflammation.
“The initial patient had a tremendously positive outcome, almost immediately, with continued improvement to the point of symptom resolution at four weeks,” Zoga said. “We have been surprised at some outcomes, including near 100 per cent resolution of phantosmia in some patients, throughout the trial.”
Follow-up was obtained for 37 patients (65 per cent), with 22 (59 per cent) of the 37 reporting improved symptoms at one week post-injection. Of these 22, 18 (82 per cent) reported significant progressive improvement by one month post-procedure. At three months, there was a mean 49 per cent improvement in symptoms (range 10 per cent to 100 per cent) among the 22 patients.
Twenty-six patients returned for a second injection given on the other side (contralateral) of their neck after at least a six-week interval.
While the second injection was not effective in patients who did not respond to the first injection, 86 per cent of patients who reported some improvement after the first injection reported additional improvement after the contralateral injection. No complications or adverse events were reported.
“Other treatments have failed to date,” Zoga said. “This injection is working.”
The study will be presented next week at the annual meeting of the Radiological Society of North America (RSNA).
–IANS
Comments are closed.